CU20200083A7 - COMPUESTO DE 2-FENILETILAMINA N-(p-HIDROXIFENIL)FENILAMINA COMO MODULADOR DE RECEPTORES TRANSMEMBRANAS METABOTRÓPICOS E IONOTRÓPICOS - Google Patents
COMPUESTO DE 2-FENILETILAMINA N-(p-HIDROXIFENIL)FENILAMINA COMO MODULADOR DE RECEPTORES TRANSMEMBRANAS METABOTRÓPICOS E IONOTRÓPICOSInfo
- Publication number
- CU20200083A7 CU20200083A7 CU2020000083A CU20200083A CU20200083A7 CU 20200083 A7 CU20200083 A7 CU 20200083A7 CU 2020000083 A CU2020000083 A CU 2020000083A CU 20200083 A CU20200083 A CU 20200083A CU 20200083 A7 CU20200083 A7 CU 20200083A7
- Authority
- CU
- Cuba
- Prior art keywords
- compound
- relates
- phenylethylamine
- diseases
- transmemembrane
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
<p>La invención se refiere a la química orgánica, farmacología y medicina, y se refiere al tratamiento de enfermedades inflamatorias y autoinmunes, tales como psoriasis, dermatitis atópica, prurigo, enfermedad de Crohn, colitis, enfermedades gastrointestinales tales como diarrea y sindrome del intestino irritable, enfermedades respiratorias tales como asma, COPD, bronquitis, rinitis, y también tos y una serie de otras enfermedades asociadas con la actividad de receptores opioides y de taquiquina y de canales de iones TRPV1 y TRPM8, usando un compuesto de 2-feniletilamina N-(p-hidroxifenilacetil)fenilalanina:</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>la invención, y también aductos farmacéuticamente aceptables, hidratos, solvatos, son agonistas de receptores opioides, agonistas de receptores de taquiquinina y de canales de iones TRPV1 y TRPM8; la invención también se refiere a composiciones farmacéuticas que comprenden una cantidad terapéuticamente efectiva del compuesto de acuerdo con la invención.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2018117463A RU2697414C1 (ru) | 2018-05-11 | 2018-05-11 | Новый антагонист тахикининовых рецепторов и его применение |
| PCT/RU2019/050060 WO2019216795A1 (ru) | 2018-05-11 | 2019-05-07 | Новый модулятор метаботропных и ионотропных трансмембранных рецепторов и его применение |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20200083A7 true CU20200083A7 (es) | 2021-06-08 |
| CU24662B1 CU24662B1 (es) | 2023-05-11 |
Family
ID=67640490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2020000083A CU24662B1 (es) | 2018-05-11 | 2019-05-07 | Compuesto de 2-feniletilamida n-(p-hidroxifenilacetil)fenilalanina como modulador de receptores transmembranas metabotrópicos e ionotrópicos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11414377B2 (es) |
| EP (1) | EP3792247A4 (es) |
| JP (1) | JP7301954B2 (es) |
| KR (1) | KR102805008B1 (es) |
| CN (1) | CN112384495B (es) |
| AU (1) | AU2019267188B2 (es) |
| CA (1) | CA3099849A1 (es) |
| CL (1) | CL2020002908A1 (es) |
| CU (1) | CU24662B1 (es) |
| EA (1) | EA202092712A1 (es) |
| GE (1) | GEP20237454B (es) |
| IL (1) | IL278603B2 (es) |
| MA (1) | MA52582A (es) |
| MX (1) | MX2020012035A (es) |
| PH (1) | PH12020551928A1 (es) |
| RU (1) | RU2697414C1 (es) |
| SG (1) | SG11202011189TA (es) |
| WO (1) | WO2019216795A1 (es) |
| ZA (1) | ZA202007027B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2697414C1 (ru) * | 2018-05-11 | 2019-08-14 | Общество с ограниченной ответственностью "АЙ БИ ДИ Терапевтикс" | Новый антагонист тахикининовых рецепторов и его применение |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4579841A (en) * | 1981-07-20 | 1986-04-01 | University Patents, Inc. | Dipeptide derivatives having opiate activity |
| US5610145A (en) * | 1994-04-15 | 1997-03-11 | Warner-Lambert Company | Tachykinin antagonists |
| JP3506714B2 (ja) * | 1995-02-22 | 2004-03-15 | ノバルティス・アクチエンゲゼルシャフト | １−アリール−２−アシルアミノ−エタン化合物およびニューロキニン特にニューロキニン１アンタゴニストとしてのそれらの用途 |
| MY132550A (en) * | 1996-08-22 | 2007-10-31 | Novartis Ag | Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists |
| GB9907571D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Compounds |
| JP2003530381A (ja) | 2000-04-06 | 2003-10-14 | アストラゼネカ・アクチエボラーグ | 化合物 |
| AU2001246999A1 (en) | 2000-04-06 | 2001-10-23 | Astrazeneca Ab | New neurokinin antagonists for use as medicaments |
| SE0003476D0 (sv) | 2000-09-28 | 2000-09-28 | Astrazeneca Ab | Compounds |
| EP1295599A1 (en) | 2001-09-21 | 2003-03-26 | Boehringer Ingelheim International GmbH | Method for the treatment of prevention of atopic dermatitis |
| RU2309144C2 (ru) * | 2005-03-25 | 2007-10-27 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фенилсодержащие n-ацильные производные аминов, способ их получения, фармацевтическая композиция и их применение в качестве противовоспалительных и анальгетических средств |
| CN107739316B (zh) * | 2017-11-14 | 2020-07-14 | 中国医科大学 | 一种溴代酪氨酸生物碱类化合物及其制备方法和用途 |
| RU2697414C1 (ru) * | 2018-05-11 | 2019-08-14 | Общество с ограниченной ответственностью "АЙ БИ ДИ Терапевтикс" | Новый антагонист тахикининовых рецепторов и его применение |
-
2018
- 2018-05-11 RU RU2018117463A patent/RU2697414C1/ru active
-
2019
- 2019-05-07 SG SG11202011189TA patent/SG11202011189TA/en unknown
- 2019-05-07 CU CU2020000083A patent/CU24662B1/es unknown
- 2019-05-07 IL IL278603A patent/IL278603B2/en unknown
- 2019-05-07 JP JP2021513748A patent/JP7301954B2/ja active Active
- 2019-05-07 CA CA3099849A patent/CA3099849A1/en active Pending
- 2019-05-07 CN CN201980044155.6A patent/CN112384495B/zh active Active
- 2019-05-07 MA MA052582A patent/MA52582A/fr unknown
- 2019-05-07 EA EA202092712A patent/EA202092712A1/ru unknown
- 2019-05-07 US US17/054,686 patent/US11414377B2/en active Active
- 2019-05-07 KR KR1020207035511A patent/KR102805008B1/ko active Active
- 2019-05-07 EP EP19799411.4A patent/EP3792247A4/en active Pending
- 2019-05-07 AU AU2019267188A patent/AU2019267188B2/en active Active
- 2019-05-07 WO PCT/RU2019/050060 patent/WO2019216795A1/ru active Application Filing
- 2019-05-07 MX MX2020012035A patent/MX2020012035A/es unknown
- 2019-05-07 GE GEAP201915511A patent/GEP20237454B/en unknown
-
2020
- 2020-11-09 CL CL2020002908A patent/CL2020002908A1/es unknown
- 2020-11-11 PH PH12020551928A patent/PH12020551928A1/en unknown
- 2020-11-11 ZA ZA2020/07027A patent/ZA202007027B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GEP20237454B (en) | 2023-01-10 |
| JP2021523235A (ja) | 2021-09-02 |
| MX2020012035A (es) | 2021-03-29 |
| RU2697414C1 (ru) | 2019-08-14 |
| EP3792247A4 (en) | 2022-01-12 |
| WO2019216795A1 (ru) | 2019-11-14 |
| ZA202007027B (en) | 2022-08-31 |
| AU2019267188A1 (en) | 2020-11-26 |
| MA52582A (fr) | 2021-03-17 |
| SG11202011189TA (en) | 2020-12-30 |
| US20210070692A1 (en) | 2021-03-11 |
| IL278603B1 (en) | 2023-11-01 |
| CA3099849A1 (en) | 2019-11-14 |
| KR20210008061A (ko) | 2021-01-20 |
| CL2020002908A1 (es) | 2021-03-26 |
| EP3792247A1 (en) | 2021-03-17 |
| PH12020551928A1 (en) | 2021-06-14 |
| IL278603B2 (en) | 2024-03-01 |
| JP7301954B2 (ja) | 2023-07-03 |
| KR102805008B1 (ko) | 2025-05-09 |
| AU2019267188B2 (en) | 2024-02-15 |
| CN112384495B (zh) | 2023-07-18 |
| IL278603A (es) | 2021-03-01 |
| US11414377B2 (en) | 2022-08-16 |
| BR112020022807A2 (pt) | 2021-02-02 |
| CU24662B1 (es) | 2023-05-11 |
| CN112384495A (zh) | 2021-02-19 |
| EA202092712A1 (ru) | 2021-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PA8805801A1 (es) | Agonistas novedosos de los receptores de glucorticoides | |
| EA033497B1 (ru) | 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1 | |
| PH12022551750A1 (en) | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases | |
| MX2022005335A (es) | Bloqueadores de canales ionicos cargados y metodos de uso. | |
| MX390698B (es) | Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos. | |
| NZ747259A (en) | Soluble c5ar antagonists | |
| BR112018067312A2 (pt) | compostos e composições farmacêuticas dos mes-mos para o tratamento da fibrose | |
| BR112012033075A2 (pt) | composto piperidina substituído antagonista de receptor c5a, composição farmacêutica, e, uso do composto. | |
| PH12020551501A1 (en) | Oxadiazole transient receptor potential channel inhibitors | |
| MX2022000397A (es) | Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. | |
| CU24487B1 (es) | Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror | |
| MX2020014085A (es) | Compuestos. | |
| PH12019502853A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| EA201992328A1 (ru) | Фармацевтическая композиция, содержащая ленватиниба мезилат | |
| CL2017002957A1 (es) | Benzamidas sustituidas y métodos para utilizarlas | |
| MX2022006736A (es) | Combinacion de un antagonista del receptor lpa1 de azetidina con pirfenidona y/o nintedanib para su uso en el tratamiento de enfermedades fibroticas. | |
| MX2022007171A (es) | Compuestos cíclicos y métodos de uso de estos. | |
| MX377867B (es) | Derivado de amina cíclica y uso médico del mismo. | |
| MA43256B1 (fr) | Procédé pour préparer une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique | |
| CU20200083A7 (es) | COMPUESTO DE 2-FENILETILAMINA N-(p-HIDROXIFENIL)FENILAMINA COMO MODULADOR DE RECEPTORES TRANSMEMBRANAS METABOTRÓPICOS E IONOTRÓPICOS | |
| CO2021014223A2 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios | |
| BR112023017612A2 (pt) | Compostos agonistas do receptor beta do hormônio da tireoide | |
| MX380424B (es) | Compuestos heterociclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de n-metil-d-aspartato (nmda) nr2b. | |
| EA202190966A1 (ru) | Пролекарства антагонистов cgrp | |
| NZ603966A (en) | Nicotinic receptor non-competitive antagonists |